About us

Who are we

Cardio3 BioSciences, headquartered in Mont-Saint-Guibert (Belgium), is a leading edge company founded in 2007 and focused on the research, development and commercialization of regenerative therapies of cardiovascular diseases.

Our lead product, C-Cure®, is a cell therapy using autologous stem cells differentiated precursors, also called cardiopoietic cells. This second generation cell therapy was developed on extensive basic research conducted with the Cardiovascular Center of Aalst, Belgium, Mayo Clinic®, Rochester (MN), USA and is currently being evaluated in human clinical studies.